Next-era sensors are expected to supply improved reliability and precision.

BD, JDRF partner to accelerate advancement of glucose-sensing technology for T1D JDRF and BD today announced an expansion of their existing collaboration centered on Type 1 diabetes to accelerate the advancement of BD’s proprietary glucose-sensing technology that has shown guarantee in providing extremely accurate and reliable continuous glucose details. The study expansion is section of the JDRF-HCT Sensor Initiative made to accelerate the advancement of advanced sensors that enhance the recognition of changing sugar levels. Today’s constant glucose monitoring gadgets have considerably improved glucose control in people who have T1D generalized anxiety disorder http://sertraline-hcl.net .

http://sertraline-hcl.net

BIND Therapeutics presents positive Stage 1 clinical study outcomes for BIND-014 at AACR meeting BIND therapeutics presents positive clinical data at the AACR 2013 Annual Conference for lead accurin applicant, BIND-014, in malignancy patients BIND Therapeutics, a clinical-stage biopharmaceutical company creating a new class of extremely selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Stage 1 clinical data for BIND-014, the organization's lead medication applicant, were presented today within an oral presentation in the American Association for Cancer tumor Study 2013 Annual Conference.

Other entries from category "tomography":

Random entries